Leo Pharma consolidates global commercial organization, reducing overall unit count
![Leo Pharma's head of R&D, Jörg Möller, has reduced Leo Pharma's R&D division in the past as part overall streamlining efforts, which have now also impacted the firm's commercial units | Photo: MAGNUS MØLLER](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14100904.ece/ALTERNATES/schema-16_9/doc7l9dx5weol2wxlgxcfs.jpg)
After holding meetings around the world, Leo Pharma can now announce that a number of the firm’s international sales units have been consolidated, the firm reports in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Leo Pharma poaches Novo Nordisk VP to lead US division
For subscribers